

Table 11-1. Summary of Survival of Subjects in the Full Analysis Set

		<50 mCi (N=8)	50 mCi (N=94)	>50 mCi (N=5)	All Subjects (N=107)
Patient Status [n (%)]	Dead	3 (37.5)	52 (55.3)	2 (40.0)	57 (53.3)
	Censored	5 (62.5)	42 (44.7)	3 (60.0)	50 (46.7)
Three Year Survival Proportion	KM Estimate	0.88	0.53	0.60	0.56
	95% CI	(0.39, 0.98)	(0.43, 0.63)	(0.13, 0.88)	(0.46, 0.65)
Survival Percentiles (months)	75th Percentile (95% CI)	NE (51.3, NE)	NE (NE, NE)	NE (5.7, NE)	NE (NE, NE)
	Median (95% CI)	NE (23.0, NE)	45.5 (25.4, 83.2)	NE (5.7, NE)	50.0 (27.4, NE)
	25th Percentile (95% CI)	50.0 (23.0, NE)	14.9 (11.3, 21.2)	24.2 (5.7, NE)	15.1 (12.1, 23.9)
	At Risk	8	94	5	107
	Censored	5	42	3	50

Source: [Table 14.2.1.1](#)

Note: For subjects under 3 years of age, dose groups were assigned based on the treatment dose before age adjustment (i.e. 33% or 50% dose reduction).

Note: Table 14.2.1.1 includes data collected after the data cut-off of 30 June 2019. CI = confidence interval; KM = Kaplan-Meier; NE = not estimable.